Gene editing using the CRISPR-Cas system has generated tremendous excitement and promises to revolutionise many aspects of bioscience research.
If you’ve not seen it already, do have a look at our introductory guide to CRISPR-Cas.
A PubMed search reveals over 1000 publications which mention CRISPR but until recently there were no commercial antibodies to Cas9, the protein part of the technology. That has all changed now with several companies recently adding anti-CRISPR/Cas9 antibodies to CiteAb.
These include mouse monoclonals from Diagenode and Abcam and a rabbit polyclonal from Epigentek and just today Matt added an antibody from ImmuQuest. It seems highly likely that other companies will also launch antibodies to Cas9 soon.
The first CRISPR/Cas9 antibody to be added to CiteAb was the CRISPR/Cas9 monoclonal from Diagenode which the supplier has validated for western blotting, immunofluorescence and immunoprecipitation.
Rini Mukherjee Saxena, VP for Marketing and Commercialization at Diagenode, said: “Our customers have been very pleased by the performance of our uniquely-engineered CRISPR/Cas9 antibody and have had successful results for a number of tested applications.”
Next came a rabbit polyclonal anti-CRISPR/Cas9 antibody from Epigenteck which also has supplier validation for a range of applications and is reported to bind Cas9 and nuclease deficient Cas9.
Then we added a mouse monoclonal anti-CRISPR-Cas9 antibody from Abcam which was raised against an N terminal region of the protein and has been tested for western blotting.
And finally our new antibody in today, added by Matt just a few hours ago, is a CRISP/Cas9 antibody from ImmuQuest, giving another option if you are after a mouse monoclonal.
So if you want an antibody against this protein you now have a few to chose from. We have not found any citations for these antibodies yet, so if you know of any please let us know.
We would also love to hear if you have used any of them or if you are a supplier about to launch a new anti-Cas9 antibody and we wish you all happy gene chopping, slicing and dicing 🙂
Andy and the CiteAb team.